Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hypoxic Ischemic Encephalopathy
Interventions
DRUG

Melatonin

Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.

OTHER

Magnetic Resonance Imaging

All participants will receive an MRI between 7-12 days of age.

OTHER

Pharmacokinetics

All participants will receive pharmacokinetics to test the amount of melatonin in the blood.

BEHAVIORAL

Neurological Outcome Assessment

All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.

Trial Locations (2)

32610

RECRUITING

University of Florida, Gainesville

32803

RECRUITING

Florida Hospital for Children, Orlando

All Listed Sponsors
collaborator

Thrasher Research Fund

OTHER

lead

University of Florida

OTHER